Head-To-Head Survey: GSK (NYSE:GSK) versus PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB) and GSK (NYSE:GSK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Profitability

This table compares PDS Biotechnology and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-208.95%	-83.27%
GSK	17.47%	46.75%	11.53%

Valuation and Earnings

This table compares PDS Biotechnology and GSK”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$37.61 million	($0.82)	-0.66
GSK	$43.07 billion	2.55	$7.54 billion	$3.70	14.56

GSK has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for PDS Biotechnology and GSK, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1	0	2	0	2.33
GSK	3	7	1	0	1.82

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 1,562.36%. GSK has a consensus price target of $44.13, suggesting a potential downside of 18.10%. Given PDS Biotechnology’s stronger consensus rating and higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than GSK.

Institutional & Insider Ownership

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

PDS Biotechnology has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Summary

GSK beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.